Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 6:10 PM ET


Company Overview of MediciNova Inc.

Company Overview

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic s...

4275 Executive Square

Suite 650

La Jolla, CA 92037

United States

Founded in 2000

10 Employees





Key Executives for MediciNova Inc.

Co-Founder, Chief Executive Officer, President and Executive Director
Age: 65
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Age: 47
Total Annual Compensation: $293.6K
Chief Medical Officer
Age: 49
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2014.

MediciNova Inc. Key Developments

FDA Grants Fast Track Designation for Medicinova's MN-001 (Tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis

MediciNova Inc. announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with idiopathic pulmonary fibrosis (IPF). In addition to the granting of Fast Track Designation to MN-001 for treatment of IPF, the FDA granted Orphan Drug Designation to MN-001 for treatment of IPF in October 2014, as previously announced.

MediciNova Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM

MediciNova Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 03:30 PM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Geoffrey G. O'Brien, Vice President, Yuichi Iwaki, Co-Founder, Chief Executive Officer, President and Executive Director.

MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)

MediciNova Inc. announced that the first advanced ALS patient, using non-invasive ventilation (NIV), has enrolled in the Phase 2 clinical trial evaluating MN-166 (ibudilast) in both early and advanced stage ALS. MediciNova amended the protocol to expand its recruitment to include advanced ALS patients in the trial, and this amendment was approved by FDA (U.S. Food and Drug Administration). The amended protocol now plans enrollment of 60 advanced ALS patients with NIV support in the study in addition to 60 patients without NIV support. Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, is the Principal Investigator of the study. This is a single-center, randomized, double-blind, placebo-controlled, 6-month study designed to evaluate the safety, tolerability and clinical endpoint responsiveness of MN-166 (60 mg/day) when administered as an adjunct to riluzole (100 mg/day) in subjects with ALS. The protocol amendment plans for an additional 60 advanced ALS patients, who are on NIV support, to be enrolled in the study. This study consists of two treatment arms, MN-166 and matching placebo, and randomization will occur in a 2:1 ratio (MN-166: placebo). To be eligible, subjects must have a diagnosis of sporadic or familial ALS with onset of less than 10 years from first clinical weakness prior to screening, may be on NIV support, and must be on a stable dose of riluzole for at least 1 month prior to study drug treatment. A total of approximately 120 male and female subjects from 18 to 80 years old, inclusive, will be enrolled (80 subjects in the MN-166 group; 40 subjects in the placebo group). Upon completion of the Double-blind Phase, subjects randomized to the placebo arm will continue for an additional 6 months and will receive open-label MN-166. If there are no safety or tolerability concerns in the MN-166-treated group, a decision will be made to extend participation to the MN-166-treated group into the Open-Label Extension (OLE) Phase. Otherwise, only the placebo-treated patients will participate in the OLE Phase. The primary objective is to evaluate the safety and tolerability of MN-166 60 mg/day versus placebo when administered for 6 months with riluzole. The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/day versus placebo when administered with riluzole as measured by the following assessments.

Similar Private Companies By Industry

Company Name Region
Telovax Corporation United States
Sequus Pharmaceuticals, Inc. United States
Alpine Biosciences, Inc. United States
Itero Biopharmaceuticals, Inc. United States
CellHealth Institute LLC United States

Recent Private Companies Transactions

September 1, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MediciNova Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at